Omniome Revenue and Competitors
Estimated Revenue & Valuation
- Omniome's estimated annual revenue is currently $852.5k per year.
- Omniome received $60.0M in venture funding in July 2018.
- Omniome's estimated revenue per employee is $77,500
- Omniome's total funding is $126.6M.
Employee Data
- Omniome has 11 Employees.
- Omniome grew their employee count by -39% last year.
Omniome's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | COO | Reveal Email/Phone |
3 | Chief Product Officer | Reveal Email/Phone |
4 | Chief Operating Officer | Reveal Email/Phone |
5 | Senior Manager, Software Engineering | Reveal Email/Phone |
6 | Scientist II, Manager | Reveal Email/Phone |
7 | Scientist I - Enzymology | Reveal Email/Phone |
8 | Associte Scientist | Reveal Email/Phone |
9 | Senior Mechanical Engineer | Reveal Email/Phone |
10 | Engineer 3 - System Integration | Reveal Email/Phone |
Omniome Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4280M | 11139 | -4% | $28M | $63.3B |
What Is Omniome?
Based in San Diego and founded in 2013, Omniome is a biotechnology company developing a breakthrough DNA sequencing platform that delivers highly accurate and fast results at low cost with the potential to advance cancer diagnostics, drive high fidelity single-cell applications and broadly support clinical sequencing. Our scar-free, Sequencing By Binding (SBB) technology provides enhanced precision of nucleotide and DNA matching by leveraging the natural matching ability of the polymerase, decreasing runtimes and increasing the number of samples per run. We offer a stimulating, fast-paced, start-up work environment where innovative and highly-motivated team players will thrive.
keywords:N/A
$126.6M
Total Funding
11
Number of Employees
$852.5k
Revenue (est)
-39%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Omniome News
The issue, Baker cautions, is that Omniome did not spend much time building the platform. So, although the platform's chemistry may be solid, it...
Since acquiring Omniome, PacBio is uniquely positioned as the only company with both highly accurate native long-read and short-read sequencing platforms.
SAN DIEGO, May 4, 2021 /PRNewswire/ -- Omniome, Inc., developer of an innovative DNA sequencing platform capable of delivering unsurpassed sequencing accuracy, announces the promotion of Richard Shen, PhD to the role of President. Richard brings over 20 years of leadership experience from the Ne ...
SAN DIEGO, May 4, 2021 /PRNewswire/ -- Omniome, Inc., developer of an innovative DNA sequencing platform capable of delivering unsurpassed sequencing accuracy, announces the promotion of Richard Shen, PhD to the role of President. Richard brings over 20 years of leadership experience from the ...
SAN DIEGO, March 3, 2021 /PRNewswire/ -- Omniome, Inc., developer of an innovative DNA sequencing platform capable of delivering unsurpassed sequencing accuracy, announces the appointment of Thomas O'Lenic to the newly created position of Chief Commercial Officer, effective from today's date. ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1M | 11 | N/A | N/A |
#2 | $1M | 11 | N/A | N/A |
#3 | $1M | 11 | N/A | N/A |
#4 | $1M | 11 | N/A | N/A |
#5 | $1.1M | 11 | N/A | N/A |
Omniome Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2018-07-31 | $60.0M | B | Decheng Capital | Article |